ectrum Health Grand Rapids
and Chairman of the CMM Board of Directors. "This project, along with the
increasing volume of clinical testing and cutting-edge genomics and
proteomics work underway at the CMM, demonstrates the critical role
molecular diagnostics and biotechnology will play in our region. It also
speaks to the caliber of the CMM team, under the leadership of Executive
Director Dr. Daniel Farkas, to have come so far in less than a full year of
operation."
CMM testing of COG project samples will begin in January 2008; Phase I
may be completed as early as spring. COG and CMM are working together to
identify sources of funding to expand the study to six to eight thousand
more specimens.
CMM Executive Director, Daniel H. Farkas, Ph.D., said the sample
testing and analysis would focus on tiny variations found within human
genomes, including naturally, DNA from leukemic specimens. A genome is the
complete DNA sequence present in every cell of an organism.
"The location of naturally occurring variations in human DNA, known as
Single Nucleotide Polymorphisms (SNPs), serve as signposts or markers in
the genome. Associating these SNP markers with diseases in different
individuals provides opportunity for highly specific diagnostic tests, and,
even more exciting, provides insights into what genes may be involved in
the disease process. This insight can lead to highly targeted and specific
therapies," he said. "In the COG study, the CMM will identify and catalog
about a million key SNPs in these DNAs from childhood leukemia patients so
that the COG can move forward in its important work uncovering new
approaches to identifying and combating this disease."
According to the COG, progress in the treatment of acute lymphoblastic
leukemia (ALL), the most common malignancy of children, is one of the
leading success stories in all of cancer research and cancer care. The
survival rate has risen from about 15% to 85% over the past four decades.
'/>"/>SOURCE Center for Molecular Medicine Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related biology technology :1.
Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics2.
Murray Leads Delegation in Securing $2.1 Million for Proton Therapy Center3.
AMDLs First Full Service JPGreen Health and Personal Care Center Set to Open in Hangzhou, China4.
Nano-Science Center to coordinate EU-project5.
Embla Systems in Collaboration with Beth Israel Deaconess Medical Center to Develop Cardio-Pulmonary Coupling Technology6.
Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma7.
Center for Molecular Medicine Among First Labs in Nation to Offer Groundbreaking Test to Aid in Treatment of Colorectal Cancer8.
New Cardiology Software Helps Heart Centers Manage for Optimal Clinical Performance9.
Thermo Fisher Scientific Selected by China Doping Control Center to Supply Testing Instrumentation for the 2008 Olympic Games in Beijing10.
Berlin Heart Enrolls First Patient in US Multi-Center EXCOR(R) Pediatric VAD IDE Study11.
Center for Molecular Medicine Offers Xceed Ziplex(TM) Services to Research Community